Radioconjugates?? combine ??targeted ligands?? with radioisotopes, enabling precision cancer therapy and theranostics. The ??$7.5B market by 2033?? demands strict FDA ??safety/CMC data?? for NDA/BLA approval.
The development of radioconjugates – targeted molecules designed to carry radionuclides directly to cancerous cells, lowering systemic exposure and increasing the precision of treatment.